Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 12/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 11/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 9/20 | 0.59 |
| ▸ | CHRM5 | P08912 | 9/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.59 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6420947 | 0.86 | CHRM1 (0.57) | HRH1CYP2D6CHRM1KCNH2CHRM2 | |
| SCHEMBL6419953 | 0.86 | CHRM1 (0.62) | HRH1CYP2D6CHRM1KCNH2CHRM2 | |
| SCHEMBL6420061 | 0.85 | HRH1 (0.57) | HRH1CYP2D6CHRM1KCNH2CHRM2 | |
| SCHEMBL6279358 | 0.83 | CHRM1 (0.57) | HRH1CYP2D6CHRM1KCNH2CHRM2 | |
| SCHEMBL6415652 | 0.76 | CHRM1 (0.76) | HRH1CYP2D6CHRM1KCNH2CHRM2 | |
| SCHEMBL6266812 | 0.74 | HRH1 (0.81) | HRH1CYP2D6CHRM1KCNH2CHRM2 | |
| SCHEMBL6420676 | 0.73 | HRH1 (1.00) | HRH1CYP2D6CHRM1KCNH2CHRM2 | |
| SCHEMBL6279164 | 0.73 | HRH1 (1.00) | HRH1CYP2D6CHRM1KCNH2CHRM2 | |
| SCHEMBL6280343 | 0.72 | CHRM1 (0.60) | HRH1CYP2D6CHRM1KCNH2CHRM2 | |
| SCHEMBL6415984 | 0.71 | HRH1 (0.57) | HRH1CYP2D6CHRM1KCNH2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050277645-A1 | Sleep inducing compounds and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-12-15 | — | — | US | disclosed |
| WO-2005097093-A1 | SLEEP INDUCING COMPOUNDS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277645-A1 | Sleep inducing compounds and methods relating thereto | CNR1, CNR2, MTNR1B | HRH1 104/4885CYP2D6 74/4885CHRM1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.